ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.495
      -0.34%
      Bitcoin
      65,208.92
      0.11%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Mesoblast Limited (MESO)

      7. Mesoblast Limited (MESO) News

      MESO

      Mesoblast (MESO)

      Mesoblast Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MESO
      DateTimeSourceHeadlineSymbolCompany
      04/06/20206:00AMGlobeNewswire Inc.FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRES...NASDAQ:MESOMesoblast Limited
      04/01/20206:00AMGlobeNewswire Inc.FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEWNASDAQ:MESOMesoblast Limited
      03/30/20206:00AMGlobeNewswire Inc.CLINICAL OUTCOMES OF MESOBLAST’S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLO...NASDAQ:MESOMesoblast Limited
      03/10/20206:00AMGlobeNewswire Inc.Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung DiseaseNASDAQ:MESOMesoblast Limited
      02/26/20204:59PMGlobeNewswire Inc.Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019NASDAQ:MESOMesoblast Limited
      02/25/20206:00AMGlobeNewswire Inc.Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019NASDAQ:MESOMesoblast Limited
      02/24/20206:00AMGlobeNewswire Inc.Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Ac...NASDAQ:MESOMesoblast Limited
      02/20/20206:00AMGlobeNewswire Inc.Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host DiseaseNASDAQ:MESOMesoblast Limited
      02/03/20206:00AMGlobeNewswire Inc.Mesoblast Submits Completed Biologics License Application for Ryoncil™ to US FDANASDAQ:MESOMesoblast Limited
      01/15/20206:00AMGlobeNewswire Inc.Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San FranciscoNASDAQ:MESOMesoblast Limited
      01/02/20206:00AMGlobeNewswire Inc.Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-LNASDAQ:MESOMesoblast Limited
      12/18/20196:00AMGlobeNewswire Inc.Data Monitoring Committee Completes Final Scheduled Review of Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Hea...NASDAQ:MESOMesoblast Limited
      12/17/20196:00AMGlobeNewswire Inc.Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for...NASDAQ:MESOMesoblast Limited
      11/25/20194:52PMGlobeNewswire Inc.Mesoblast Finanical Results for the Quarter Ended September 30, 2019NASDAQ:MESOMesoblast Limited
      11/21/20194:29PMGlobeNewswire Inc.Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019NASDAQ:MESOMesoblast Limited
      11/07/20196:05AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      11/01/20196:06AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      10/22/20196:02AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      10/16/20196:17PMGlobeNewswire Inc.Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic...NASDAQ:MESOMesoblast Limited
      10/10/20196:05AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      10/04/20196:05AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      10/03/20197:59AMGlobeNewswire Inc.Mesoblast Completes Successful Institutional Capital Raising of A$75 MillionNASDAQ:MESOMesoblast Limited
      10/03/20196:05AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      09/11/20196:37AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      09/09/20197:40PMGlobeNewswire Inc.Mesoblast Corporate Update: Analyst CallNASDAQ:MESOMesoblast Limited
      09/09/20197:38PMGlobeNewswire Inc.Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Ce...NASDAQ:MESOMesoblast Limited
      09/09/20196:14AMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:MESOMesoblast Limited
      09/06/20196:36AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      08/30/20196:05AMEdgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:MESOMesoblast Limited
      08/29/20195:50PMGlobeNewswire Inc.Mesoblast Reports 2019 Full Year ResultsNASDAQ:MESOMesoblast Limited
       Showing the most relevant articles for your search:NASDAQ:MESO